SCHEMBL13878744

SCHEMBL13878744

CCN1CCN(c2cc(C(=O)Nc3ccc(C)c(NC(=O)c4cnc(Nc5cc(N6CCOCC6)nc(C)n5)s4)c3)cc(C(F)(F)F)c2)CC1

nearest known ligand 0.61

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
BRAF P15056 11/20 0.61
RAF1 P04049 8/20 0.61
ABL1 P00519 3/20 0.57
BCR P11274 2/20 0.57
HDAC1 Q13547 2/20 0.57
CSF1R P07333 1/20 0.55
AURKA O14965 1/20 0.53
FLT3 P36888 1/20 0.53
LCK P06239 2/20 0.52
MAPK14 Q16539 1/20 0.52
INSR P06213 1/20 0.51
LYN P07948 1/20 0.51
HCK P08631 1/20 0.51
SRC P12931 1/20 0.51
KDR P35968 1/20 0.51
PKMYT1 Q99640 1/20 0.49
SIK1 P57059 1/20 0.49
SIK2 Q9H0K1 1/20 0.49
SIK3 Q9Y2K2 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13878745 0.96 ABL1 (0.61) BRAFRAF1ABL1BCRHDAC1
SCHEMBL13878749 0.90 LYN (0.53) BRAFRAF1ABL1BCRHDAC1
SCHEMBL13878750 0.89 ABL1 (0.56) BRAFRAF1ABL1BCRHDAC1
SCHEMBL1704880 0.88 ABL1 (0.64) BRAFRAF1ABL1BCRHDAC1
SCHEMBL13878753 0.88 CSF1R (0.56) BRAFRAF1ABL1BCRHDAC1
SCHEMBL13878743 0.88 LYN (0.51) BRAFRAF1ABL1BCRHDAC1
SCHEMBL1704685 0.88 RAF1 (0.54) BRAFRAF1ABL1BCRHDAC1
SCHEMBL1704444 0.87 LCK (0.61) BRAFRAF1LCK
SCHEMBL13878739 0.86 BRAF (0.58) BRAFRAF1CSF1RLCKMAPK14
SCHEMBL13878805 0.85 LYN (0.55) BRAFRAF1ABL1BCRHDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090105250-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2009-04-23 US disclosed
US-20090105250-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2009-04-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105250-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS ABL1, BCR, PDGFRB BRAF 8/4885RAF1 10/4885ABL1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.